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Abstract
Background: Clinical guidelines for depression in adults recommend the use of outcome measures and stepped
care models in routine care. Such measures are based on symptom severity, but response to treatment is likely to
also be influenced by personal and contextual factors. This observational study of a routine clinical sample sought
to examine the extent to which “symptom severity measures” and “complexity measures” assess different aspects of
patient experience, and how they might relate to clinical outcomes, including disengagement from treatment.
Methods: Subjects with symptoms of depression (with or without comorbid anxiety) were recruited from people
referred to an established Primary Care Mental Health Team using a stepped care model. Each participant
completed three baseline symptom measures (the Personal Health Questionnaire (PHQ), Generalised Anxiety
Disorder questionnaire (GAD) and Clinical Outcomes in Routine Evaluation (CORE-10)), and two assessments of
“case complexity” (the Minnesota-Edinburgh Complexity Assessment Measure (MECAM) and a local complexity
assessment). Clinician perception of likely completion of treatment and patient recovery was also assessed.
Outcome measures were drop out and clinical improvement on the PHQ.
Results: 298 subjects were recruited to the study, of whom 258 had a sufficient dataset available for analysis. Data
showed that the three measures of symptom severity used in this study (PHQ, GAD and CORE-10) seemed to be
measuring distinct characteristics from those associated with the measures of case complexity (MECAM, previous
and current problem count). Higher symptom severity scores were correlated with improved outcomes at the end
of treatment, but there was no association between outcome and complexity measures. Clinicians could predict
participant drop-out from care with some accuracy, but had no ability to predict outcome from treatment.
Conclusions: These results highlight the extent to which drop-out complicates recovery from depression with or
without anxiety in real-world settings, and the need to consider other factors beyond symptom severity in planning
care. The findings are discussed in relation to a growing body of literature investigating prognostic indicators in the
context of models of collaborative care for depression.
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Background
Clinical guidelines for the management of depression
recommend the use of clinical outcome measures and
stepped care models in routine care [1], but it can be
difficult for health services to match individual patients
to the most appropriate intervention, and outcomes are
often poor. Large studies in the UK and the USA have
found that as few as 22% of patients receive adequate
care [2], that half of patients show no response to treat-
ment [3]; and that only 30% of cases conclude with a
“planned ending” [4].
“Collaborative care” is an approach to the delivery of
evidence-based mental health care for primary care
patients which seeks to address these problems [5]. It in-
cludes three core elements: team-based multidisciplinary
care delivery, implementation of a stepped care model
(in which the intensity of care is stepped up or down
depending on response to treatment), and the systematic
collection of clinical outcome data to inform decisions
about treatment [6–8]. The data chosen to comprise
such “measurement-based care” conventionally measures
depressive symptoms, adherence to treatment and side
effects [9].
Guidance on depression care issued by the UK
National Centre for Health and Care Excellence
(NICE) recognises that “a wide range of biological,
psychological and social factors, which are not captured
well by current diagnostic systems, have a significant
impact on the course of depression and the response to
treatment” [10].
Researchers have called for investigation of treatment
factors that extend beyond the choice of therapies imple-
mented [3]. These influences include service-side factors,
such as the attitude and aptitude of the treating clini-
cians [11]. Adherence to treatment is improved by good
communication, management of expectations, patient
activation and shared decision making [12–14]. Un-
planned drop-out from care is an important adverse
outcome, since the opportunity to modify treatment to
better meet patient needs has been lost. Although im-
portant, none of these contextual influences are captured
in the measures of symptom severity conventionally used
to deliver collaborative care [15].
In practice, clinical assessments are based on case
formulations that consider social, developmental and
psychological factors, and take place in teams which
should have the ability to reflect on their own style of
engagement with patients.
Two forms of assessment were investigated: symptom
severity measures (using the PHQ, GAD and CORE-10)
and case complexity measures (using the MECAM and a
bespoke case complexity instrument). The measures are
described in more detail in the Methods section. This
study aimed to investigate the feasibility of measuring a
broader range of contextual factors when planning care
for people with depression (with or without comorbid
anxiety), and to assess the association of those factors
with clinical outcomes, including drop out from
treatment.
Methods
The service described in this paper has implemented a
stepped care programme of treatment for depression in
keeping with NICE guidance since its inception in 2004.
The service model is described in detail elsewhere [16].
It includes the use of routine symptom severity measures
(PHQ and GAD) to guide the use of brief psychological
therapies by mental health clinicians working in a Pri-
mary Care Mental Health Team, but supervised from
secondary care. Patients can access guided self-help,
antidepressant medicines and/or (typically) 4–6 sessions
of therapies such as Interpersonal Therapy and Cogni-
tive Behavioural Therapy. Patients not responding to
these interventions have prompt access to psychology,
psychotherapy and/or psychiatry assessments, and ulti-
mately to longer-term pharmacological and psycho-
logical therapies in secondary care.
Subjects with symptoms of depression defined as a
score of five or more on the PHQ were recruited from
people referred to a Primary Care Mental Health Team
based in a town near a large urban centre in Scotland.
They were included in the study whether or not they
had comorbid anxiety symptoms as measured by the
GAD. The PCMHT provides a service to patients aged
18 years or more, who are referred by their GP with a
new case of depression, anxiety, low mood, adjustment
disorder or some combination of these problems. A
“new” case was defined as having been well for 6 months
prior to the onset of current mood problems, or having
been referred within 2months of onset of treatment in
primary care of the current episode.
People presenting with a primary alcohol problem, a
primary drug problem, depression as part of bipolar
affective disorder, and those with a terminal illness,
medical or psychiatric emergencies or current psychosis
were referred for more appropriate forms of care and
hence excluded from this study, in keeping with
standard local NHS procedures.
Before the first appointment, an information pack was
sent to every patient outlining the clinical service they
would receive, and inviting them to participate in this
research study, with an information sheet and copy of
the consent form. At the first appointment, clinicians
reviewed the clinical and research information with the
patient and invited them to consent to the research
programme. If the patient chose not to consent, the
appointment continued with “treatment as usual” as de-
scribed in existing treatment protocols. If the patient did
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consent to participate, the following assessments were
completed before continuing treatment as described in
existing protocols.
The assessment was in four parts:
1. Collection of demographic information (age,
gender, ethnicity, postcode and employment status)
2. Completion of clinical symptom severity measures
at each visit: the Personal Health Questionnaire
(PHQ), Generalised Anxiety Disorder questionnaire
(GAD) and Clinical Outcomes in Routine
Evaluation (CORE-10)
3. Completion of complexity measures at initial visit
only: the Minnesota-Edinburgh Complexity Assess-
ment Measure (MECAM) and the local complexity
measure.
4. The clinician’s view about whether the patient was
(a) likely to attend further treatment visits, and (b)
whether they felt the patient’s symptoms were likely
to improve with an intervention of 5 sessions or
less. These “engagement and prognosis” questions
were asked at the initial visit only.
The PHQ is a self-reported, nine item questionnaire
for the assessment of low mood. It incorporates DSM-IV
depression diagnostic criteria, and scoring is based on
the frequency of symptoms during the previous 2 weeks.
It can be administered repeatedly to track the clinical
course during treatment. Scores greater than 4, 9, 14
and 19 or more represent mild, moderate, moderately
severe and severe depression respectively [17]. A
reduction in score of five points or more is generally
considered to represent a clinically significant im-
provement [17, 18].
The GAD is a seven item self-reported questionnaire
used for assessment of generalised anxiety disorder that
may be completed by the clinician or patient. Like the
PHQ, scoring is based on the frequency of symptoms in the
previous 2 weeks. Scores greater than 4, 9 and 14 points or
more represent mild, moderate or severe anxiety [19].
The 34-item CORE-OM Clinical Outcomes in Routine
Evaluation tool is a generic measure of psychological dis-
tress which covers a range of presenting problems [20].
The CORE-10 is a 10-item version of the full measure,
and is used as a screening tool and outcome measure
when the CORE-OM is considered too long for routine
use. The measure includes two questions each about
anxiety and depression, and one question each about
trauma, physical problems and risk to self. A further
three items enquire about day to day functioning, close
relationships and social relationships. The clinical cut-
off score for general psychological distress is 11 [21].
The Minnesota Edinburgh Complexity Assessment
Method (MECAM [22]) is a clinician-rated measure
which was designed to encourage a holistic assessment
of patient needs, and initially developed for use in pri-
mary care in the UK. It asks 11 questions in four do-
mains: Health and Wellbeing, Social Environment,
Health Literacy and Communication and Action [23].
The items are scored on a four-point scale, as shown in
Appendix 2.
A local indicator of case complexity was developed
that could be completed by the assessing clinician at the
end of the first visit. The indicator used a range of fac-
tors derived from a review of 20 team clinical case notes
and relevant literature [24–27]. Indicators of case com-
plexity comprised information that would be routinely
collected as part of a standard psychiatric assessment,
and included 12 “current difficulties” (such as childcare,
money or housing problems), 15 “past difficulties” (such
as a history of physical, sexual or emotional abuse, or
parental alcohol or drug dependence), current receipt of
benefits, alcohol consumption, smoking, presence of a
long-term health condition, or presence of two or more
health conditions. These measures were collated into
counts. The full list of questions in the case complexity
measure is shown in Appendix 1.
In addition, the treating clinician was asked to state at
baseline whether they thought that “the patient’s prob-
lems will improve with an intervention of 5 sessions or
less”, and whether the clinician thought that “this patient
is more than 50% likely to attend their next appointment
with you?”
All clinical information was held securely on NHS
systems in keeping with NHS Greater Glasgow and
Clyde policies on information governance.
Data for analysis was anonymised by removing names,
date of birth, and the Community Health Index number
(CHI; the unique identifier for all patients in the NHS in
Scotland) from all research records. The CHI number
was replaced with a personal research ID number
independent of CHI. The key linking CHI and research
database identification numbers was held securely in
keeping with standard protocols.
Baseline characteristics of the participants such as gen-
der, age, ethnicity and health conditions, as well as base-
line complexity and symptom severity measures are
presented descriptively. Deprivation was measured using
the Scottish Index of Multiple Deprivation, the official
tool used by Scottish Government to identify areas of
poverty and inequality in Scotland [28]. Associations
between complexity measures and symptom severity
measures at baseline were examined.
An exploratory Principal Component Analysis (PCA)
was performed to assess the pattern of associations be-
tween the complexity measures and symptom severity
measures at baseline. Wilcoxon-Mann-Whitney tests
were used to compare complexity measures and
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symptom severity measures between groups defined by
the clinician’s two “engagement and prognosis” questions
at the first visit.
We first investigated factors associated with the likeli-
hood of drop out from the service. Drop out was defined
as failure to return for treatment visits after the initial
assessment visit. Drop out was summarised in relation
to baseline patient characteristics, complexity and symp-
tom severity measures, and the clinician assessment of
whether the patient was likely to disengage, and associa-
tions were assessed with Fisher’s Exact Test p-values.
Univariate and multivariable logistic regression models
were also used to explore these associations.
We then investigated the factors associated with
treatment response, defined as achieving at least a 5
point improvement in PHQ score, amongst those who
attended at least one treatment visit. This is compatible
with the “reliable change index” for the PHQ used by
other researchers [3]. Descriptive statistics, and Fisher’s
Test p-values are reported. Univariate and multivariable
logistic regression models were also performed.
Results
Baseline characteristics
927 referrals were made to the service during the study
period, and 576 patients attended at least one appoint-
ment, making them eligible to join the study. Of that
number, 298 subjects were recruited to the study, of
whom 258 had an adequate dataset available for analysis.
Participant characteristics at baseline are summarised
in Table 1. Participants were 159 women and 99 men,
with a mean age of 38.6 years. Participants were drawn
from each of the five deprivation quintiles in the Scottish
Index of Multiple Deprivation. The distribution in this
study was broadly similar to that of the catchment area.
Thirty-two percent lived in the most deprived quintile,
15% in the second most deprived, 19% in the third most
deprived, 10% in the fourth most deprived and 25% in
the least deprived quintile. Our study population was
slightly less deprived than the population in the overall
catchment area of the study with 26, 15, 20, 15 and 23%
in the most to least deprived quintiles respectively [29].
Nineteen percent were receiving one or more of the
following benefits: job-seeker’s allowance, employment
support allowance, disability living allowance, or free
school meals for children.
Ten percent of subjects reported that they drank to an
“increased-risk” or “higher-risk” level as defined by NICE
guidance (at that time, above 21 units of alcohol per week
for men and 14 units per week for women) [30]. 24% of
subjects reported that they currently smoked cigarettes.
Sixty-four percent of participants described themselves as
“healthy”, with 22% reporting at least one long-term health
condition and 14% having two or more long-term condi-
tions. Just over half of participants said that they were both
prescribed, and taking, antidepressant medicine.
None of the differences between male and female
patients were statistically significant.
Association between baseline symptoms severity
measures and case “complexity”
There were moderate, but highly significant associations
between the complexity measures and symptom severity
measures at baseline (Table 2).
Table 1 Baseline characteristics
Male Female All
N 99 159 258
Age (years) Mean (SD) 39.5 (13.4) 38.0 (12.4) 38.6 (12.8)
Current smoker N (%) 30 (30%) 31 (19%) 61 (24%)
Current Antidepressant Use N (%) 59 (60%) 81 (51%) 140 (54%)
Complexity Measures
Past Difficulties Count Mean (SD) 3.0 (2.5) 3.0 (2.2) 3.0 (2.3)
Current Difficulties Count Mean (SD) 4 (2.1) 4.4 (2) 4.2 (2)
MECAM Mean (SD) 18.9 (5.7) 19.1 (5) 19.0 (5.3)
Symptom Scores
PHQ Mean (SD) 16 .0 (5.6) 15.9 (5.6) 16.0 (5.6)
GAD Mean (SD) 13.5 (4.8) 13.8 (4.7) 13.7 (4.7)
CORE-10 Mean (SD) 21.2 (6) 21.5 (6.4) 21.3 (6.2)
Clinician Assessments
Do you think this patient is more than 50% likely to attend their next appointment with you?
“Yes” N (%) 86 (87%) 147 (92%) 233 (90%)
Do you think this patient’s problems will improve with an intervention of 5 sessions or less?
“Yes” N (%) 71 (72%) 127 (80%) 198 (77%)
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There were statistically signifiant associations between
each of the symptom severity measures (PHQ-GAD
(0.65), PHQ-CORE (0.72), GAD-CORE (0.72)) and each
of the complexity measures (MECAM-Past (0.38),
MECAM-Current (0.53), Past-Current (0.23)), all p <
0.001).
An exploratory Principal Components Analysis of
complexity measures and symptom severity measures at
baseline identified two components that explained 49.7
and 20.3% of the total variation, respectively; Fig. 1 sug-
gests that the first principal component measures gen-
eral case severity, being positively correlated with all six
scores. The second component differentiates between
the complexity measures (positively correlated) and
symptom severity measures (negatively correlated). This
interpretation of the second principal component,
coupled with the observation that the complexity and
outcomes measures show a clear separation in terms of
their patterns of correlations with the two principal
components, indicate that the two groups of measures
are describing distinct features of patients’ clinical condi-
tion at baseline.
Complexity scores were also correlated with clinician
views on prognosis at first assessment. Patients whose
clinicians thought they were likely to improve with an
intervention of 5 sessions or less had significantly lower
problem counts and MECAM scores, and lower PHQ
and CORE-10 scores (Table 3). Patients who the clin-
ician thought were likely to continue with treatment had
a lower number of current problems (though not previ-
ous problems) and lower MECAM scores. There were
no significant associations between clinician assessments
about probable attendance and any of the symptom
severity scores at baseline.
Association between baseline measures and drop out
from treatment
Being a current smoker was associated with a signifi-
cantly increased likelihood of drop out from treatment,
but age, gender and antidepressant use were not (Table
4). Neither the symptom severity measures nor the com-
plexity measures were associated with dropping out
from treatment. The clinician assessment about who
would drop out of care was significantly associated with
subsequent drop out. Although clinicians only predicted
25 subjects to be unlikely to attend the next visit, 80% of
their predictions were correct. Logistic regression ana-
lyses (Table 5) broadly supported these findings.
Association between baseline measures and clinical
improvement
There was a high attrition rate over time, with 159 of
258 participants returning for a second appointment,
and only 39 completing the 5th treatment visit (Table 6).
Clinical improvement was defined as the achievement
of a 5-point or greater reduction in PHQ score, at the
last visit attended after the initial assessment, up to the
5th treatment visit, therefore the 99 participants who did
not attend at least one treatment visit after the initial as-
sessment were not included in the analyses looking at
clinical improvement. Of the 159 participants that
attended at least one treatment visit after the initial
assessment, 98 achieved at least a 5-point improvement
in PHQ score (Table 4).
Younger patients who engaged with the service were
more likely to show an improvement in PHQ scores, but
there was no difference by gender, or by antidepressant
use (Table 4). None of the complexity measures showed
any association with treatment response, but there was
an association with baseline PHQ and GAD, with more
severely affected patients showing the greatest improve-
ments. Interestingly, clinicians were unable to predict
which patients were most likely to improve within 5
treatment sessions. On multivariable regression, only
baseline PHQ remained a significant predictor of treat-
ment response, amongst the baseline symptom severity
measures. Otherwise, only younger age remained as an
independent predictor of improvement in PHQ scores.
Discussion
This exploratory study sought to investigate the associa-
tions between symptom severity scores and a range of
contextual factors on clinical outcomes, including drop
out from treatment. It was based on observation of a
routine clinical sample, conducted in a team providing
care in a collaborative, stepped care model. The patient
group were a typical UK cohort in terms of demograph-
ics and symptom severity.
Table 2 Spearman correlation coefficients between baseline complexity measures and symptom severity measures, with p-values
Complexity Measures
Past Difficulties Current Difficulties MECAM
Symptom severity measures PHQ r = 0.24
p < 0.001
r = 0.26
p < 0.001
r = 0.41
p < 0.001
GAD r = 0.17
p = 0.005
r = 0.15
p = 0.016
r = 0.25
p < 0.001
CORE-10 r = 0.28
p < 0.001
r = 0.22
p < 0.001
r = 0.35
p < 0.001
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The use of measurement-based care to improve out-
comes depends on three premises: firstly, that the mea-
surements accurately assess relevant influences on
treatment, secondly that they can inform meaningful
choices between treatment options, and thirdly that they
can facilitate the early identification of potential harm
[9]. Such harm might include clinical deterioration,
emerging risks to safety or the likelihood of dropping
out of treatment altogether.
Main findings
The majority of patients presented with “moderately
severe” or “severe” depression, which is consistent with
other studies of “low intensity” interventions [31], in-
cluding the Second UK National Audit of psychological
therapies [3]. Recruitment to the study was 45% of
eligible subjects, comparable to other work in Improving
Access to Psychological Therapies (IAPT) settings in
England [32]. Drop-out rates were high, with 61% of
patients attending a second appointment, and only 15%
attending for five appointments. This is higher than drop-
out rates of 20–40% observed in other mental health set-
tings [33, 34], though it should be noted that the typical
number of planned care visits in UK primary care mental
health settings is only about six [4]. Nonetheless, the mean
improvement scores on the PHQ for patients who
adhered to treatment was clinically significant and statisti-
cally significant between all treatment visits apart from be-
tween the 4th and 5th treatment visit. Symptom severity
scores showed the biggest decrease between the first and
second visit, with treatment continuing beyond four visits
associated with less improvement.
The three measures of symptom severity (PHQ, GAD
and CORE-10) were significantly correlated with each
other, as were the three measures of case complexity
(MECAM, previous problem count and current problem
count). The symptom severity and complexity measures
were also correlated with each other. However principal
components analysis suggested that symptom and com-
plexity measures at intake were associated with different
aspects of patient characteristics at baseline.
Neither symptom severity nor complexity measures
were associated with drop out from treatment when
considered individually. On a multivariable analysis,
current smoking status and the MECAM were associ-
ated with drop out. The effect with MECAM was small
(OR 0.93). This is a surprising finding, since the com-
plexity measures included socioeconomic characteristics
such as unemployment or being in receipt of benefits;
these would usually be considered adverse prognostic in-
dicators. The absence of an association between experi-
ence of past adversity and drop out from treatment was
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Fig. 1 Correlations between input variables and the first two components from a Principal Components Analysis of complexity measures
(Previous Problem Count, Current Problem Count, MECAM) and symptom severity measures (PHQ, GAD, CORE-10) at baseline
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surprising, given the extent to which Adverse Childhood
Experiences (ACEs) are known to increase the preva-
lence of depression and the risk of poor outcomes in
treatment [35, 36].
This study confirms clinician’s inability to predict the
likely outcome of treatment, and the importance of baseline
illness severity in predicting improvement. Although the
MECAM had a modest association with drop out from
treatment, clinician impression was more influential. We
found that clinicians could predict with some accuracy who
would drop out of treatment. This effect remained influen-
tial (OR 8.59) in the multivariable analysis, although one
third of patients who dropped out of treatment were
not identified by the clinician. The accuracy of the
clinician assessment in relation to drop out of treat-
ment may be an early indication of difficulties in the
therapeutic relationship (making drop-out more
likely), or perhaps reflects a complex qualitative intuition
expressed by clinicians which is not fully captured by the
quantitative measures.
Baseline scores for the PHQ and GAD predicted
treatment response, with more severe scores being
more likely to show an improvement in PHQ of at
least 5 points. On the multivariable analysis, only
PHQ and younger age were associated with improve-
ment. Clinician judgement showed no ability to deter-
mine who was most likely to improve with treatment.
Although baseline characteristics may be associated
with outcome from treatment, research to date has not
been able to define clear “steps” which stepped care
models might use. Two recent meta-analyses using indi-
vidual patient level data found that outcomes after Cog-
nitive Behavioural Therapy (CBT) were independent of
baseline severity for both CBT [37] and antidepressants
or CBT [38]. The optimal treatment choices at each step
may not be clear [39]. Treatment guidelines therefore
differ: guidance from the National Institute for Health
and Care Excellence (NICE) in England reserves anti-
depressant treatment for more severe depression (PHQ
score 18+) [1], whereas American guidelines for the
treatment of depression in primary care advocates both
antidepressant and psychotherapy for patients with a
PHQ score above 10 [40].
Pragmatic trials of smaller numbers of prognostic indi-
cators [41, 42] have confirmed the importance of baseline
severity of depression and anxiety, as well as other factors
such as age, gender, living alone and marital status.
Strengths and limitations
One strength of the study was that it took place in a
routine care setting, since participants in randomised
controlled trials for depression and anxiety may not be
representative of those who attend primary and psy-
chiatric care clinics [39].
Table 3 Mean (SD) of complexity measures and symptom scores in relation to clinician assessments, with p-values from Wilcoxon-
Mann-Whitney tests
Do you think this patient’s problems will improve with an intervention of 5 sessions or less?
Yes No p-value
N 198 60
Complexity Measures
Previous Problem Count 2.7 (2.2) 4.0 (2.5) p < 0.001
Current Problem Count 4.0 (2.0) 4.8 (2.1) p = 0.013
MECAM 18.3 (4.7) 21.5 (6.2) p < 0.001
Symptom Scores
PHQ 15.4 (5.6) 17.7 (5.4) p = 0.009
GAD 13.5 (4.7) 14.4 (4.7) p = 0.161
CORE-10 20.8 (6.2) 23.3 (5.9) p = 0.004
Do you think this patient is more than 50% likely to attend their next appointment with you?
Yes No p-value
N 233 25
Complexity Measures
Previous Problem Count 3.0 (2.3) 3.0 (2.2) p = 0.964
Current Problem Count 4.1 (2.0) 4.8 (1.8) p = 0.061
MECAM 18.7 (5.0) 21.8 (6.9) p = 0.040
Symptom Scores
PHQ 15.8 (5.5) 17.1 (6.3) p = 0.380
GAD 13.6 (4.7) 14.6 (4.8) p = 0.270
CORE-10 21.2 (6.3) 23.1 (5.6) p = 0.111
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Table 4 Association between baseline patient characteristics, complexity and symptom severity measures, and clinician assessments,
and patient drop out and, for those who engaged, treatment response. Drop out defined as failure to attend treatment visits after
the initial assessment. N total is everyone who attended the initial visit, and N engaged is the participants that attended the initial
visit and at least one treatment visit. Treatment response defined as achievement of at least a 5 point improvement in PHQ score at
the last attended visit up to the 5th treatment visit. P-values from Fisher’s Exact Tests
Drop out PHQ Response
N Total N Dropout (%) p-value N Engaged N Improvement (%) p-value
All 258 99 159 98
Age (years) 18–29
30–44
45+
72
104
82
33 (46%)
35 (34%)
31 (38%)
p = 0.257 39
69
51
30 (77%)
43 (61%)
25 (47%)
p = 0.026
Gender Male
Female
99
159
45 (46%)
54 (34%)
p = 0.067 54
105
35 (65%)
63 (60%)
p = 0.608
Current smoker Yes
No
61
197
33 (54%)
66 (34%)
p = 0.006 28
131
22 (79%)
76 (58%)
p = 0.054
Current AD Use Yes
No
140
118
55 (39%)
44 (37%)
p = 0.798 85
74
56 (66%)
42 (57%)
p = 0.256
Prev Prob Count Low (≤2)
High (≥3)
129
129
49 (38%)
50 (39%)
p = 1.000 80
79
47 (59%)
51 (65%)
p = 0.515
Curr Prob Count Low (≤4)
High (≥5)
149
109
60 (40%)
39 (39%)
p = 0.518 89
70
56 (63%)
42 (60%)
p = 0.744
MECAM Low (≤18)
High (≥19)
125
133
49 (39%)
50 (38%)
p = 0.799 76
83
43 (57%)
55 (66%)
p = 0.254
PHQ None/Mild/Moderate
Moderate severe
Severe
98
79
125
41 (42%)
27 (34%)
31 (38%)
p = 0.574 57
52
50
26 (46%)
34 (65%)
38 (76%)
p = 0.005
GAD Minimum/Mild
Moderate
Severe
54
79
125
23 (43%)
33 (42%)
43 (34%)
p = 0.446 31
46
82
15 (48%)
19 (41%)
64 (78%)
p < 0.001
CORE-10 Low/Mild/Moderate
Moderate severe
Severe
97
59
102
43 (44%)
15 (25%)
41 (40%)
p = 0.054 54
44
61
29 (54%)
25 (57%)
44 (72%)
p = 0.096
Clinician assessment(a) Yes
No
233
25
79 (34%)
20 (80%)
p < 0.001
Clinician assessment(b) Yes
No
129
30
80 (62%)
18 (60%)
p = 0.838
Table 5 Association between baseline patient characteristics, symptom scores, complexity scores, and clinician’s assessment(a, b), and
treatment response, defined as achievement of a 5 point reduction in PHQ-9 score at last attended visit up to the 5th treatment
visit, and drop out form the service, defined as failure to return for treatment after the initial assessment visit. Data analysed using
univariate and multivariable logistic regression models. Results presented as odds ratios, with 95% confidence intervals and p-values.
Best-fitting multivariable models found by backward selection from all predictors
Predictor Effect Drop out from service Achievement of 5 point reduction in PHQ-9
Univariable Multivariable Univariate Multivariable
OR (95% CI), p-value OR (95% CI), p-value OR (95% CI), p-value OR (95% CI), p-value
Age per 10 years 1.03 (0.85, 1.26), p = 0.756 0.72 (0.54, 0.94), p = 0.017 0.71 (0.52, 0.95), p = 0.022
Gender Female vs. Male 0.62 (0.37, 1.03), p = 0.066 0.81 (0.41, 1.6), p = 0.555
Current Smoker Yes vs. No 2.34 (1.31, 4.22), p = 0.004 2.49 (1.3, 4.81), p = 0.006 2.65 (1.06, 7.6), p = 0.048
Current AD Use Yes vs. No 1.09 (0.66, 1.81), p = 0.742 1.47 (0.77, 2.81), p = 0.239
Prev Prob Count per problem 1.02 (0.92, 1.14), p = 0.701 1.13 (0.97, 1.32), p = 0.131
Curr Prob Count per problem 0.94 (0.82, 1.06), p = 0.299 1.02 (0.87, 1.2), p = 0.82
MECAM per point 0.97 (0.93, 1.02), p = 0.275 0.93 (0.88, 0.98), p = 0.01 1.03 (0.97, 1.1), p = 0.333
PHQ-9 per point 1 (0.95, 1.04), p = 0.953 1.13 (1.07, 1.21), p < 0.001 1.13 (1.07, 1.21), p < 0.001
GAD per point 0.96 (0.91, 1.01), p = 0.131 1.17 (1.09, 1.27), p < 0.001
CORE-10 per point 0.98 (0.94, 1.02), p = 0.416 1.09 (1.04, 1.16), p = 0.002
Clinician assessment(a) No vs. Yes 7.8 (3.03, 24.13), p < 0.001 8.59 (3.16, 27.94), p < 0.001 –
Clinician assessment(b) Yes vs. No – 1.09 (0.47, 2.43), p = 0.838
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However, these advantages are also associated with
some weaknesses. Antidepressants and psychological
therapy were used in varying combinations for different pa-
tients. The study took place in a team designed to deliver
“brief interventions”, which in a UK primary care mental
health setting are typically of 6–10 sessions [4, 43].
Epidemiological studies suggest that the mean dur-
ation of a depressive episode is about 4 months [2]. In
trials both natural remission (43% within 6 months) and
placebo response rates (49%) in primary care trials are
high [15, 44]; but this uncontrolled study was not able to
investigate their effects.
Studies of Adverse Childhood Experiences show that
not all negative life experiences have the same impact on
later-life outcomes [45], yet in this study there was no
adjustment for the severity or chronicity of those expe-
riences. Likewise, no enquiry was made about potential
protective factors, even though these may influence
outcomes [46, 47].
Conclusions
This study highlights the importance of drop-out from
care as an important therapeutic consideration. Drop-out
has been found to be more likely early in treatment,
particularly after the second visit. Strategies to minimise
drop out include attending to health literacy and patient
expectations of treatment [48, 49], establishing a thera-
peutic alliance [50], and of “person-centred” approaches
to care and shared decision making [51].
King commented that “real-world data show that
outcomes from psychotherapy are messy and difficult
to predict” [52]. This observational study confirms
that condition severity is the best indicator of out-
come, and finds that clinician judgement may be a
useful predictor of potential drop out from treatment.
Further research into the characteristics of clinician
prediction might usefully complement other measures
used in collaborative care.
Supplementary information
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